Each 100g gel contains 50mg Tazarotene
Mechanism of Action
Tazarotene is a retinoid prodrug which is converted to its active form.
Tazarotenic acid binds to all three members of the retinoic acid receptor (RAR) family: RARα,RARβ, and RARγ, but shows relative selectivity for RARβ, and RARγ and may modify gene expression.
Tazarotene Domina Gel are indicated for the topical treatment of patients with stable plaque psoriasis up to 20%bodysurface area involvement .
Tazarotene Domina Gel is also indicated for the topical treatment of patients with facial acne vulgaris of mild to moderate severity.
Dosage and Administration
For topical use only. is not for ophthalmic, oral, or intravaginal use.
Wash hands thoroughly after application.
Tazaroten Domina may cause fetal harm when administered to a pregnant woman.
Tazarotene Gel is contraindicated in women who are or may become pregnant. It is contraindicated in individuals who have shown hypersensitivity to any of its components.
Warnings and Precautions:
Tazarotene Domina Gel did not induce allergic contact sensitization, phototoxicity photoallergy.
Psoriasis: The most frequent adverse events are: pruritus ,burning/stinging, erythema, worsening of psoriasis, irritation, skin pain , rash, desquamation, irritant contact dermatitis, skin inflammation, fissuring, bleeding, and dry skin.
Acne: The most frequent adverse events are: desquamation ,burning/stinging ,dry skin ,erythema and pruritus, irritation, skin pain, fissuring, localized edema and skin discoloration.
The following adverse reactions have been identified during post marketing use of Tazarotene Domina Gel including blister ,rash ,skin discoloration and pain.
Concomitant dermatologic medications and cosmetics that have a strong drying effect should be avoided. Concomitant use of tazarotene did not affect the pharmacokinetics of norethindrone and ethenyl estradiol over a complete cycle.
Teratogenic Effects: Pregnancy Category X
Tazarotene Gel may cause fetal harm when administered to a pregnant female and is contraindicated during pregnancy. Safety in pregnant females has not been established. The potential risk to the fetus outweighs the potential benefit to the mother from Tazarotene Gel during pregnancy; therefore, Tazarotene Gel should be discontinued as soon as pregnancy is recognized.
For females who can become pregnant: Your doctor will order a pregnancy test for you within 2 weeks before you begin treatment with Tazarotene Gel to be sure that you are not pregnant.
- Begin treatment with Tazarotene Gel during a normal menstrual period
- Use an effective form of birth control during treatment with Tazarotene Gel.
There is no information regarding the presence of tazarotene in human milk, the effects on the breastfed infant, or the effects on milk production. the developmental and health benefits of breastfeeding should be considered along with the mother’s clinical need for Tazarotene Gel and any potential adverse effects on the breastfed child from Tazarotene Gel or from the underlying maternal condition
Excessive topical use of tazarotene Gel may lead to marked redness, peeling, or discomfort. Oral ingestion of the drug may lead to the same adverse effects as those associated with excessive oral intake of Vitamin A (hypervitaminosis A) or other retinoids. If oral ingestion occurs, the patient should be monitored, and appropriate supportive measures should be administered as necessary.